Evaluation of Cryptococcus neoformans galactoxylomannan-protein conjugate as vaccine candidate against murine cryptococcosis

Vaccine

Volumn 29, Issue 10, 2011, Pages 1891-1898

  Chow, Siu Kei ^a   Casadevall, Arturo ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Capsule; Cryptococcus neoformans; ELISA; Galactoxylomannan; Immunoglobin; Polysaccharide

Indexed keywords

1 CYANO 4 DIMETHYLAMINOPYRIDINIUM TETRAFLUOROBORATE; BACTERIAL ANTIGEN; BORIC ACID; BOVINE SERUM ALBUMIN; FREUND ADJUVANT; FUNGUS VACCINE; GALACTOXYLOMANNAN BOVINE SERUM ALBUMIN CONJUGATE; GALACTOXYLOMANNAN PROTECTIVE ANTIGEN CONJUGATE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN M; QUIL A; REAGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACILLUS ANTHRACIS; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOFLUORESCENCE TEST; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, FUNGAL; ANTIGENS, BACTERIAL; BACTERIAL TOXINS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FUNGAL VACCINES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, INBRED BALB C; OPSONIN PROTEINS; POLYSACCHARIDES, BACTERIAL; SERUM ALBUMIN, BOVINE; SURVIVAL ANALYSIS; VACCINES, CONJUGATE;

EID: 79951726019     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.12.134     Document Type: Article

References (54)

1. Casadevall A., Perfect J.R. Cryptococcus neoformans 1998, ASM Press.
2. Bose I., Reese A.J., Ory J.J., Janbon G., Doering T.L. A yeast under cover: the capsule of Cryptococcus neoformans. Eukaryot Cell 2003, 2(4 (August)):655-663.
3. Blandamer A., Danishefsky I. Investigations on the structure of the capsular polysaccharide from Cryptococcus neoformans type B. Biochim Biophys Acta 1966, 117(2 (April)):305-313.
4. Vaishnav V.V., Bacon B.E., O'Neill M., Cherniak R. Structural characterization of the galactoxylomannan of Cryptococcus neoformans Cap67. Carbohydr Res 1998, 306(1-2 (January)):315-330.
5. Levitz S.M., Specht C.A. The molecular basis for the immunogenicity of Cryptococcus neoformans mannoproteins. FEMS Yeast Res 2006, 6(4 (June)):513-524.
6. McFadden D.C., De Jesus M., Casadevall A. The physical properties of the capsular polysaccharides from Cryptococcus neoformans suggest features for capsule construction. J Biol Chem 2006, 281(4 (January)):1868-1875.
7. Heiss C., Klutts J.S., Wang Z., Doering T.L., Azadi P. The structure of Cryptococcus neoformans galactoxylomannan contains beta-d-glucuronic acid. Carbohydr Res 2009, 344(7 (May)):915-920.
8. De Jesus M., Chow S.K., Cordero R.J., Frases S., Casadevall A. Galactoxylomannans from Cryptococcus neoformans varieties neoformans and grubii are structurally and antigenically variable. Eukaryot Cell 2010, 9(7 (July)):1018-1028.
9. Pericolini E., Cenci E., Monari C., De Jesus M., Bistoni F., Casadevall A., et al. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8. Cell Microbiol 2006, 8(2 (February)):267-275.
10. Pericolini E., Gabrielli E., Bistoni G., Cenci E., Perito S., Chow S.K., et al. Role of CD45 signaling pathway in galactoxylomannan-induced T cell damage. PLoS One 2010, 5(9):e12720.
11. Pericolini E., Gabrielli E., Cenci E., De Jesus M., Bistoni F., Casadevall A., et al. Involvement of glycoreceptors in galactoxylomannan-induced T cell death. J Immunol 2009, 182(10 (May)):6003-6010.
12. Villena S.N., Pinheiro R.O., Pinheiro C.S., Nunes M.P., Takiya C.M., DosReis G.A., et al. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand. Cell Microbiol 2008, 10(6 (June)):1274-1285.
13. De Jesus M., Nicola A., Fraser S., Lee I.R., Mieses S., Casadevall A. Galactoxylomannan-mediated immunological paralysis results from specific B cell depletion in the context of widespread immune system damage. J Immunol 2009, 183(6):3885-3894.
14. Andersson B., Blomgren H. Evidence for thymus-independent humoral antibody production in mice against polyvinylpyrrolidone and E. coli lipopolysaccharide. Cell Immunol 1971, 2(5 (October)):411-424.
15. Feldmann M., Basten A. The relationship between antigenic structure and the requirement for thymus-derived cells in the immune response. J Exp Med 1971, 134(1 (July)):103-119.
16. De Jesus M., Nicola A.M., Rodrigues M.L., Janbon G., Casadevall A. Capsular localization of the Cryptococcus neoformans polysaccharide component galactoxylomannan. Eukaryot Cell 2009, 8(1 (January)):96-103.
17. Devi S.J., Schneerson R., Egan W., Ulrich T.J., Bryla D., Robbins J.B., et al. Cryptococcus neoformans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun 1991, 59(10 (October)):3700-3707.
18. Dromer F., Salamero J., Contrepois A., Carbon C., Yeni P. Production, characterization, and antibody specificity of a mouse monoclonal antibody reactive with Cryptococcus neoformans capsular polysaccharide. Infect Immun 1987, 55(3 (March)):742-748.
19. Black S.B., Shinefield H.R., Ling S., Hansen J., Fireman B., Spring D., et al. Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia. Pediatr Infect Dis J 2002, 21(9 (September)):810-815.
20. Ellis R.W., Granoff D.M. Development and clinical uses of Haemophilus B conjugate vaccines 1994, Informa Healthcare. 1st ed.
21. Casadevall A., Mukherjee J., Devi S.J., Schneerson R., Robbins J.B., Scharff M.D. Antibodies elicited by a Cryptococcus neoformans-tetanus toxoid conjugate vaccine have the same specificity as those elicited in infection. J Infect Dis 1992, 165(6 (June)):1086-1093.
22. Mukherjee J., Casadevall A., Scharff M.D. Molecular characterization of the humoral responses to Cryptococcus neoformans infection and glucuronoxylomannan-tetanus toxoid conjugate immunization. J Exp Med 1993, 177(4 (April)):1105-1116.
23. Mukherjee S., Lee S., Mukherjee J., Scharff M.D., Casadevall A. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice. Infect Immun 1994, 62(3 (March)):1079-1088.
24. Chang Y.C., Kwon-Chung K.J. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 1994, 14(7 (July)):4912-4919.
25. Moyrand F., Janbon G. UGD1, encoding the Cryptococcus neoformans UDP-glucose dehydrogenase, is essential for growth at 37°C and for capsule biosynthesis. Eukaryot Cell 2004, 3(6 (December)):1601-1608.
26. Dubois M., Gilles K.A., Hamilton J.K., Rebers P.A., Smith F. Colorimetric method for determination of sugars and related substances. Anal Chem 1956, 28(3):350-356.
27. Lees A., Nelson B.L., Mond J.J. Activation of soluble polysaccharides with 1-cyano-4-dimethylaminopyridinium tetrafluoroborate for use in protein-polysaccharide conjugate vaccines and immunological reagents. Vaccine 1996, 14(3 (February)):190-198.
28. Suarez N., Massaldi H., Franco Fraguas L., Ferreira F. Improved conjugation and purification strategies for the preparation of protein-polysaccharide conjugates. J Chromatogr A 2008, 1213(2 (December)):169-175.
29. Lees A., Morris S.C., Thyphronitis G., Holmes J.M., Inman J.K., Finkelman F.D. Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody. J Immunol 1990, 145(11 (December)):3594-3600.
30. Zaragoza O., Casadevall A. Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 2004, 6:10-15.
31. Zaragoza O., Alvarez M., Telzak A., Rivera J., Casadevall A. The relative susceptibility of mouse strains to pulmonary Cryptococcus neoformans infection is associated with pleiotropic differences in the immune response. Infect Immun 2007, 75(6 (June)):2729-2739.
32. Mukherjee S., Feldmesser M., Casadevall A. J774 murine macrophage-like cell interactions with Cryptococcus neoformans in the presence and absence of opsonins. J Infect Dis 1996, 173(5 (May)):1222-1231.
33. Casadevall A., Mukherjee J., Scharff M.D. Monoclonal antibody based ELISAs for cryptococcal polysaccharide. J Immunol Methods 1992, 154(1 (September)):27-35.
34. Cherniak R., Cheeseman M.M., Reyes G.H., Reiss E., Todaro F. Enhanced binding of capsular polysaccharides of Cryptococcus neoformans to polystyrene microtitration plates for enzyme-linked immunosorbent assay. Diagn Clin Immunol 1988, 5(6):344-348.
35. Bhattacharjee A.K., Bennett J.E., Glaudemans C.P. Capsular polysaccharides of Cryptococcus neoformans. Rev Infect Dis 1984, 6(5 (September-October)):619-624.
36. Cherniak R., Sundstrom J.B. Polysaccharide antigens of the capsule of Cryptococcus neoformans. Infect Immun 1994, 62(5 (May)):1507-1512.
37. Fonseca F.L., Frases S., Casadevall A., Fischman-Gompertz O., Nimrichter L., Rodrigues M.L. Structural and functional properties of the Trichosporon asahii glucuronoxylomannan. Fungal Genet Biol 2009, 46(6-7 (June-July)):496-505.
38. Callahan L.T., Woodhour A.F., Meeker J.B., Hilleman M.R. Enzyme-linked immunosorbent assay for measurement of antibodies against pneumococcal polysaccharide antigens: comparison with radioimmunoassay. J Clin Microbiol 1979, 10(4 (October)):459-463.
39. James P.G., Cherniak R. Galactoxylomannans of Cryptococcus neoformans. Infect Immun 1992, 60(3 (March)):1084-1088.
40. Eckert T.F., Kozel T.R. Production and characterization of monoclonal antibodies specific for Cryptococcus neoformans capsular polysaccharide. Infect Immun 1987, 55(8 (August)):1895-1899.
41. Fleuridor R., Zhong Z., Pirofski L. A human IgM monoclonal antibody prolongs survival of mice with lethal cryptococcosis. J Infect Dis 1998, 178(4 (October)):1213-1216.
42. Hacariz O., Sayers G., McCullough M., Garrett M., O'Donovan J., Mulcahy G. The effect of Quil A adjuvant on the course of experimental Fasciola hepatica infection in sheep. Vaccine 2009, 27(1 (January)):45-50.
43. Sun H.X., Xie Y., Ye Y.P. Advances in saponin-based adjuvants. Vaccine 2009, 27(12 (March)):1787-1796.
44. Takahashi H., Takeshita T., Morein B., Putney S., Germain R.N., Berzofsky J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs. Nature 1990, 344(6269 (April)):873-875.
45. Mukherjee J., Nussbaum G., Scharff M.D., Casadevall A. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell. J Exp Med 1995, 181(1 (January)):405-409.
46. Nussbaum G., Cleare W., Casadevall A., Scharff M.D., Valadon P. Epitope location in the Cryptococcus neoformans capsule is a determinant of antibody efficacy. J Exp Med 1997, 185(4 (February)):685-694.
47. Zaragoza O., Casadevall A. Antibodies produced in response to Cryptococcus neoformans pulmonary infection in mice have characteristics of nonprotective antibodies. Infect Immun 2004, 72(7 (July)):4271-4274.
48. Griffin F.M., Griffin J.A., Leider J.E., Silverstein S.C. Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. J Exp Med 1975, 142(5 (November)):1263-1282.
49. Shaw D.R., Griffin F.M. Phagocytosis requires repeated triggering of macrophage phagocytic receptors during particle ingestion. Nature 1981, 289(5796 (January)):409-411.
50. Goren M.B. Experimental murine cryptococcosis: effect of hyperimmunization to capsular polysaccharide. J Immunol 1967, 98(5 (May)):914-922.
51. Germann T., Bongartz M., Dlugonska H., Hess H., Schmitt E., Kolbe L., et al. Interleukin-12 profoundly up-regulates the synthesis of antigen-specific complement-fixing IgG2a, IgG2b and IgG3 antibody subclasses in vivo. Eur J Immunol 1995, 25(3 (March)):823-829.
52. Fleuridor R., Lees A., Pirofski L. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection. J Immunol 2001, 166(2 (January)):1087-1096.
53. Nakouzi A., Zhang T., Oscarson S., Casadevall A. The common Cryptococcus neoformans glucuronoxylomannan M2 motif elicits non-protective antibodies. Vaccine 2009, 27(27 (June)):3513-3518.
54. Devi S.J. Preclinical efficacy of a glucuronoxylomannan-tetanus toxoid conjugate vaccine of Cryptococcus neoformans in a murine model. Vaccine 1996, 14(9 (June)):841-844.